AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel …
20 hours ago · AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate.
Phase 2 schizophrenia fails will cost AbbVie about $3.5B
18 hours ago · The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission.
AbbVie to Record $3.5 Billion Charge on Failed Cerevel Drug (1)
19 hours ago · AbbVie Inc. will record a $3.5 billion charge after a schizophrenia drug it gained in the purchase of Cerevel Therapeutics Inc. failed in clinical trials. The experimental drug, emraclidine, failed to hit its goal in two mid-stage trials, Abbvie said in November. The shares fell 0.3% in trading before US markets opened Friday.
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel …
1 day ago · AbbVie has recorded an approximately $3.5 billion impairment charge related to its purchase of Cerevel Therapeutics, according to a new financial filing.Through its $8.7 billion acquisition, which completed last summer, AbbVie got a pipeline of experimental brain drugs, including one that looked to be a promising new therapy for schizophrenia.
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia …
18 hours ago · AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
Dec 6, 2023 · Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline; Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions; Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 · Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease; Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
After one disappointment, AbbVie gets good news out of Cerevel …
Dec 11, 2024 · AbbVie touted the promise of a more robust neurology pipeline by adding Cerevel's drugs to fight Parkinson's and schizophrenia, along with Darigabat, a Phase 2 candidate to treat treatment...
AbbVie acquires Cerevel Therapeutics for $8.7bn - Yahoo Finance
Aug 2, 2024 · AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in an $8.7bn deal. In December 2023, the companies signed a definitive agreement under which AbbVie...
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel …
Dec 9, 2024 · The news comes almost one month to the day after AbbVie announced the shocking Phase II failure of another key Cerevel asset, emraclidine, which had been under development for schizophrenia. The double trial failure sent AbbVie’s shares plummeting and brought into question the Big Pharma’s long-term neuro strategy, which had put emraclidine ...
- Some results have been removed